エンテカビルの市場規模、予測、市場考察（2032年）

薬剤のサマリー

エンテカビルは強力かつ選択的なB型肝炎ウイルスの複製阻害剤です。HBe抗原陽性とHBe抗原陰性のラミブジン未治療のB型慢性肝炎（CHB）患者において、1日0.5mgのETV投与は、ラミブジン（LAM）と比較して、より強力なウイルス抑制、より高い生化学的寛解率、より良好な肝組織像の向上と関連しています。3年間のETV治療後、患者の大部分（94％）は、感度の高いPCRアッセイで検出されない血清HBV DNAレベルに達する可能性があります。LAM耐性HBV変異体を有する患者のETV治療では、1日1mgの高用量が必要ですが、3年後に強力なHBV抑制が達成されるのは40％に過ぎず、遺伝子型HBV耐性の累積率は1年目の6％から3年目には30％以上に増加します。ETVによるHBV耐性はラミブジン未治療患者ではまれであり、治療3年後の耐性率は1％未満と報告されています。結論として、ETVは耐性に対する遺伝的障壁が高い非常に強力な抗HBV薬であり、ラミブジン未治療のCHB患者において非常に有効であり、長期的な治療にはもっとも有望ですが、LAM耐性HBV変異体を保有するCHB患者にはあまり適していません。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）におけるB型慢性肝炎向けエンテカビルについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 B型慢性肝炎におけるエンテカビルの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 エンテカビル市場の評価

• B型慢性肝炎におけるエンテカビルの市場見通し
• 主要7市場と中国の分析
  • 主要7市場と中国のB型慢性肝炎向けエンテカビルの市場規模
• 市場の分析：国別
  • 米国のB型慢性肝炎向けエンテカビルの市場規模
  • ドイツのB型慢性肝炎向けエンテカビルの市場規模
  • 英国のB型慢性肝炎向けエンテカビルの市場規模
  • 中国のB型慢性肝炎向けエンテカビルの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Entecavir, Clinical Trial Description, 2023
• Table 2: Entecavir, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: Entecavir Market Size in the 7MM and China, in USD million (2019-2032)
• Table 6: Entecavir Market Size in the US, in USD million (2019-2032)
• Table 7: Entecavir Market Size in Germany, in USD million (2019-2032)
• Table 8: Entecavir Market Size in France, in USD million (2019-2032)
• Table 9: Entecavir Market Size in Italy, in USD million (2019-2032)
• Table 10: Entecavir Market Size in Spain, in USD million (2019-2032)
• Table 11: Entecavir Market Size in the UK, in USD million (2019-2032)
• Table 12: Entecavir Market Size in Japan, in USD million (2019-2032)
• Table 13: Entecavir Market Size in China, in USD million (2019-2032)

List of Figures

• Figure 1: Entecavir Market Size in the 7MM and China, USD million (2019-2032)
• Figure 2: Entecavir Market Size in the United States, USD million (2019-2032)
• Figure 3: Entecavir Market Size in Germany, USD million (2019-2032)
• Figure 4: Entecavir Market Size in France, USD million (2019-2032)
• Figure 5: Entecavir Market Size in Italy, USD million (2019-2032)
• Figure 6: Entecavir Market Size in Spain, USD million (2019-2032)
• Figure 7: Entecavir Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Entecavir Market Size in Japan, USD million (2019-2032)
• Figure 9: Entecavir Market Size in China, USD million (2019-2032)

"Entecavir Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about entecavir for chronic hepatitis B in the seven major markets and China. A detailed picture of the entecavir for chronic hepatitis B in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China for the study period 2019 -2032 is provided in this report along with a detailed description of the entecavir for chronic hepatitis B. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the entecavir market forecast analysis for chronic hepatitis B in the 7MM and China, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic hepatitis B.

Drug Summary:

Entecavir is a potent and selective inhibitor of hepatitis B virus replication. In HBeAg-positive and HBeAg-negative lamivudine-naive patients with chronic hepatitis B (CHB), treatment with ETV at a dose of 0.5 mg daily is associated with a more potent viral suppression, a higher rate of biochemical remission and a greater improvement of liver histology compared to Lamivudine (LAM). After 3 years of ETV treatment, the majority of patients (94%) may achieve serum HBV DNA levels undetectable by sensitive PCR assays. ETV treatment of patients with LAM-resistant HBV mutants requires a higher daily dose of 1 mg yet, potent HBV suppression at 3 years is achieved only in 40% of them while the cumulative rate of genotypic HBV resistance increases from 6% in the first year to >30% in year 3. ETV resistance of HBV is rare in lamivudine-naive patients with a reported rate of <1% after three years of treatment. In conclusion, ETV is a very potent anti-HBV drug with a high genetic barrier to resistance, highly effective in lamivudine-naive CHB patients and most promising for their long-term treatment but not very suitable for CHB patients harboring LAM-resistant HBV mutants.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the entecavir description, mechanism of action, dosage and administration, research and development activities in chronic hepatitis B.
• Elaborated details on entecavir regulatory milestones and other development activities have been provided in this report.
• The report also highlights the entecavir research and development activities in chronic hepatitis B across the United States, Europe, Japan, and China.
• The report also covers the patents information with expiry timeline around entecavir.
• The report contains forecasted sales of entecavir for chronic hepatitis B till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic hepatitis B.
• The report also features the SWOT analysis with analyst views for entecavir in chronic hepatitis B.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Entecavir Analytical Perspective by DelveInsight

• In-depth Entecavir Market Assessment

This report provides a detailed market assessment of entecavir for chronic hepatitis B in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China. This segment of the report provides forecasted sales data from 2024 to 2032.

• Entecavir Clinical Assessment

The report provides the clinical trials information of entecavir for chronic hepatitis B covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for chronic hepatitis B is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence entecavir dominance.
• Other emerging products for chronic hepatitis B are expected to give tough market competition to entecavir and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of entecavir in chronic hepatitis B.
• Our in-depth analysis of the forecasted sales data of entecavir from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the entecavir in chronic hepatitis B.

Key Questions:

• What is the product type, route of administration and mechanism of action of entecavir?
• What is the clinical trial status of the study related to entecavir in chronic hepatitis B and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the entecavir development?
• What are the key designations that have been granted to entecavir for chronic hepatitis B?
• What is the forecasted market scenario of entecavir for chronic hepatitis B?
• What are the forecasted sales of entecavir in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China?
• What are the other emerging products available and how are these giving competition to entecavir for chronic hepatitis B?
• Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

Table of Contents

1. Report Introduction

2. Entecavir Overview in Chronic hepatitis B

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Entecavir Market Assessment

• 5.1. Market Outlook of Entecavir in Chronic hepatitis B
• 5.2. 7MM and China Analysis
  • 5.2.1. Market Size of Entecavir in the 7MM and China for Chronic hepatitis B
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Entecavir in the United States for Chronic hepatitis B
  • 5.3.2. Market Size of Entecavir in Germany for Chronic hepatitis B
  • 5.3.3. Market Size of Entecavir in France for Chronic hepatitis B
  • 5.3.4. Market Size of Entecavir in Italy for Chronic hepatitis B
  • 5.3.5. Market Size of Entecavir in Spain for Chronic hepatitis B
  • 5.3.6. Market Size of Entecavir in the United Kingdom for Chronic hepatitis B
  • 5.3.7. Market Size of Entecavir in Japan for Chronic hepatitis B
  • 5.3.8. Market Size of Entecavir in China for Chronic hepatitis B

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options